Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Ingrezza price, strengths & recalls

Brand of valbenazine (generic)

Pharmacies pay $8,117.59 for 30 capsules of Ingrezza 40 mg capsule this week, and from $8,117.59 to $8,754.46 across its 3 priced strengths and forms. Its official label last changed on April 22, 2026.

Brand
Pharmacies pay$8,117.59for 30 capsules of 40 mg capsule+4.5% in 4 weeks
Fair cash price
$9,345.73
Strengths
3
Makers
1
Updated
Nov 11

Ingrezza price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
40 mg capsule Brand$270.59$8,117.59 / 30 capsules+4.5%+4.4%
60 mg capsule Brand$291.82$8,754.46 / 30 capsules+3.0%+3.0%
80 mg capsule Brand$291.82$8,754.46 / 30 capsules+3.0%+3.0%

The lowest cost per capsule is 40 mg capsule at $270.59. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Ingrezza vs generic valbenazine

There is no generic version of Ingrezza on the market yet. Its last listed patent or exclusivity runs to August 10, 2040 - generics often follow, though court cases and settlements can move the date either way.

GenericValbenazine prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
No ongoing recallsNone on record

What did you pay for ingrezza? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedApril 22, 2026
Version34 of 17
EffectiveApr 17, 2026
Read the label

These highlights do not include all the information needed to use INGREZZA or INGREZZA SPRINKLE safely and effectively. See full prescribing information for INGREZZA. INGREZZA® (valbenazine) capsules, for oral useINGREZZA® SPRINKLE (valbenazine) capsules, for oral useInitial U.S. Approval: 2017

This drug has a boxed warning

WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON'S DISEASE

VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician.

Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease [see Warnings and Precautions (5.1)].

WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON'S DISEASE

See full prescribing information for complete boxed warning.

• Increases the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease (5.1)

• Balance risks of depression, and suicidal ideation and behavior with the clinical need for treatment of chorea when considering the use of INGREZZA or INGREZZA SPRINKLE (5.1)

• Monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior (5.1)

• Inform patients, caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician (5.1)

• Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation (5.1)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA209241 · Neurocrine
First approved
April 11, 2017 (9 years ago)
Latest approved change
October 23, 2026
Approved label
PDF, Oct 27, 2026
Generic makers
None on the market
Last patent listed
August 10, 2040
Exclusivity ends
August 18, 2030

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Ingrezza questions

How much does ingrezza cost without insurance?

Pharmacies pay about $8,117.59 for 30 capsules of ingrezza 40 mg capsule ($270.59 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $9,345.73. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Ingrezza?

Yes: valbenazine. Compare valbenazine prices.

Is ingrezza in shortage?

No shortage is reported for ingrezza right now. We check the national shortage list every day.

Has ingrezza been recalled?

No recalls are on record for ingrezza.

When did the ingrezza label last change?

The official label was last updated on April 22, 2026 (version 34). See what changed.

Talk about ingrezza

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.